Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1991-07-29
1999-03-02
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 79, 435 795, 435 405, 435960, 436519, 436811, G01N 3353
Patent
active
058769480
ABSTRACT:
Method for treatment of a disease in a patient characterized by accumulation of .beta.-amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist. Methods for screening for compounds useful for treating such a disease are also disclosed.
REFERENCES:
patent: 3862114 (1975-01-01), Scandrett
patent: 4059693 (1977-11-01), Stewart
patent: 4666829 (1987-05-01), Glenner et al.
Guiroy et al, "Peptides Homologous to Amyloid Beta-Protein of Alzheimer's Disease Are Neurotoxic to Hippocampal Neurons in Vitro", Abstract 947B in Neurology, 40(Suppl. 1):373.
Yankner et al. "Neurotrophic and Neurotoxic Effects of Amyloid Protein: Reversal by Tachykinin Neuropeptides", Science, 250:279-282 (12 Oct. 1990).
Kowall et al. "An in vivo model for the neurodegenerative effects of .beta. amyloid and protection by substance P", Proc. Natl. Acad. Sci. USA, 88:7247-7251 (Aug. 1991).
Beal et al., "Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex," Neurology 37:1205-1208, 1987.
Bouras et al., "Substance P Immunoreactivity in Alzheimer Disease: A Study in Cases Presenting Symmetric or Asymmetric Cortical Atrophy," Alzheimer Disease and Associated Disorders 4:24-34, 1990.
Crystal et al., "Cortical Substance P-Like Immunoreactivity in Cases of Alzheimer's Disease and Senile Dementia of the Alzheimer Type," Journal of Neurochemistry 38:1781-1784, 1982.
Joachim et al., "Amuloid .beta.-protein deposition in tissues other than brain in Alzheimer's disease," Nature 341:226-230, 1989.
Kang et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," Nature 325:733-736, 1987.
Maggio, "Tachykinins," Ann. Rev. Neurosci. 11:13-28, 1988.
Quigley et al., "Substance P-Like Immunoreactive Neurons are Depleted in Alzheimer's Disease Cerebral Cortex," Neuroscience 41:41-60, 1991.
Robakis et al., "Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides," Proc. Natl. Acad. Sci. USA 84:4190-4194, 1987.
Sisodia et al., "Evidence that .beta.-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing," Science 248:492-494, 1990.
Snider et al., "A Potent Nonpeptide Antagonist of the Substance P (NK1) Receptor," Science 251:435-437, 1991.
McLean et al., "Activity and Distribution of Binding Sites in Brain of a Nonpeptide Substance P (NK1) Receptor Antagonist," Science 251:437-439, 1991.
Wirak et al., "Deposits of Amyloid .beta. Protein in the Central Nervous System of Transgenic Mice," Science 253:323-325, 1991.
Whitson et al., "Amyloid .beta. Protein Enhances the Survival of Hippocampal Neurons in Vitro," Science 243:1488-1490, 1989.
Yankner et al., "Neurotoxicity of a Fragment of the Amyloid Precursor Associated with Alzheimer's Disease," Science 245:417-420, 1989.
Duffy Patricia A.
Hutzell Paula K.
The Children's Medical Center Corporation
LandOfFree
Screening methods to identify neurotoxin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening methods to identify neurotoxin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening methods to identify neurotoxin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-421420